Management of Acute Coccidioides Infection

Initial Assessment and Risk Stratification

For patients with mild, nondebilitating symptoms or substantially improved illness at diagnosis, close observation with patient education and supportive care is appropriate, as recommended by the Infectious Diseases Society of America 1, 2
Historically, 92% of primary pulmonary coccidioidomycosis cases resolved without antifungal therapy in the pre-treatment era, indicating a high spontaneous resolution rate 3

The Infectious Diseases Society of America recommends fluconazole 400 mg daily orally as the first-line treatment for acute pulmonary coccidioidomycosis in adults with normal renal function 1, 2, 3
For severe or rapidly progressive disease, intravenous amphotericin B is recommended until clinical stabilization, followed by transition to fluconazole, as suggested by the Infectious Diseases Society of America 4, 5, 6
For pregnant patients, intravenous amphotericin B is the treatment of choice in the first trimester, while azole antifungals can be considered after the first trimester, according to the Infectious Diseases Society of America 4, 7

Lumbar puncture with CSF analysis is indicated only if patients present with unusual, worsening, or persistent headache, altered mental status, unexplained nausea or vomiting, or new focal neurologic deficit, as recommended by the Infectious Diseases Society of America 5, 6

Serial clinical assessments for 1-2 years are necessary to document resolution or identify complications early, and imaging should be performed as clinically indicated to assess pulmonary changes, according to the Infectious Diseases Society of America 4, 8

The Infectious Diseases Society of America advises against treating all seropositive patients reflexively, as 95% of uncomplicated primary infections resolve without therapy 4
The Infectious Diseases Society of America recommends against relying solely on CF antibody titers to diagnose disseminated disease, as tissue diagnosis is usually required 2
The Infectious Diseases Society of America advises against using fluconazole <400 mg daily in adults without substantial renal impairment 5, 6